Bank Of New York Mellon Corp Brainstorm Cell Therapeutics Inc. Transaction History

Bank Of New York Mellon Corp

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$1.43 - $3.3 $17,151 - $39,580	11,994 New	11,994 $39.6 Million
Q4 2022 Feb 14, 2023	BUY	$1.37 - $4.42 $16,431 - $53,013	11,994 New	11,994 $19,000
Q2 2022 Aug 15, 2022	SELL	$2.71 - $3.6 $1,956 - $2,599	-722 Reduced 5.89%	11,528 $32,000
Q4 2021 Feb 11, 2022	SELL	$2.81 - $4.23 $10,253 - $15,435	-3,649 Reduced 22.95%	12,250 $49,000
Q2 2021 Aug 11, 2021	SELL	$3.01 - $4.01 $218,778 - $291,462	-72,684 Reduced 82.05%	15,899 $60,000
Q1 2021 May 13, 2021	SELL	$3.46 - $7.88 $2,684 - $6,114	-776 Reduced 0.87%	88,583 $339,000
Q4 2020 Feb 09, 2021	SELL	$3.99 - $17.73 $3,199 - $14,219	-802 Reduced 0.89%	89,359 $404,000
Q3 2020 Nov 12, 2020	BUY	$11.19 - $16.92 $189,995 - $287,284	16,979 Added 23.2%	90,161 $1.53 Million
Q2 2020 Aug 12, 2020	BUY	$4.42 - $12.66 $263,887 - $755,839	59,703 Added 442.93%	73,182 $820,000
Q1 2020 May 06, 2020	BUY	$4.01 - $8.88 $3,103 - $6,873	774 Added 6.09%	13,479 $62,000
Q4 2019 Feb 14, 2020	SELL	$3.62 - $4.29 $6,360 - $7,537	-1,757 Reduced 12.15%	12,705 $54,000
Q1 2019 May 14, 2019	SELL	$3.37 - $4.34 $1,381 - $1,779	-410 Reduced 2.76%	14,462 $63,000
Q3 2018 Nov 09, 2018	SELL	$3.73 - $4.38 $3 - $4	-1 Reduced 0.01%	14,872 $0
Q2 2018 Aug 06, 2018	SELL	$3.12 - $5.19 $12,024 - $20,002	-3,854 Reduced 20.58%	14,873 $58,000
Q1 2018 May 15, 2018	BUY	$3.01 - $3.77 $11,600 - $14,529	3,854 Added 25.91%	18,727 $59,000
Q4 2017 Feb 09, 2018	BUY	$2.96 - $4.42 $44,024 - $65,738	14,873	14,873 $58,000

10.5M

160K

30.5K

Ticker BCLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,486,200
Market Cap $69.3M
Description
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.